Lois Frankel sold Novartis AG ADR (NYSE: NVS)
Lois Frankel (D-FL), a U.S. Representative, has disclosed 1 trade in Novartis AG ADR (NVS) since 2014, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Lois Frankel sold $1,001 - $15,000 of Novartis AG ADR (NYSE: NVS) on June 12, 2014. Since that trade, NVS is up +205.74% against the S&P 500 up +361.98%, an outperformance of -156.25%.
Data updated
Lois Frankel's NVS trades vs the price
NVS is up +205.74% since Lois Frankel sold on June 12, 2014, versus +361.98% for the S&P 500.
Performance since this trade
All Lois Frankel NVS trades
Lois Frankel & NVS trading FAQ
Is it legal for Lois Frankel to trade Novartis AG ADR (NVS) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novartis AG ADR (NVS), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Lois Frankel sell NVS?
Lois Frankel disclosed a sale of $1,001 - $15,000 of Novartis AG ADR (NVS) on June 12, 2014, according to public STOCK Act filings.
How has NVS performed since Lois Frankel's trade?
Since Lois Frankel sold NVS on June 12, 2014, the stock is up +205.74%, versus +361.98% for the S&P 500 over the same period, an outperformance of -156.25%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVS trades?
Quantellect tracks every disclosed congressional trade in Novartis AG ADR (NVS) on the Novartis AG ADR congressional trading page, which aggregates filings across all members of Congress.
Lois Frankel's NVS tradesAll congressional filings for Novartis AG ADRLois Frankel's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.